VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA, November 30, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology c
VICTORIA, British Columbia, November 22, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV"). Accordingly, it is anticipated that, effective as at the close of trading on Friday, November 25, 2022, IPA’s common shares will no longer be listed and posted for trading on the TSXV.
VICTORIA, British Columbia, October 12, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA), today announced that its subsidiary, Talem Therapeutics LLC ("Talem"), has entered into a multi-target license agreement with OmniAb, Inc., a subsidiary of Ligand Pharmaceuticals Incorporated. The agreement builds upon Talem’s extensive antibody development expertise and its access to LENSai™ in silico software technology to further the development and commerciali